Digital twin developer Unlearn has raised $50m in a series C funding round, bringing its total funding to over $130m. The funding will be used to expand the company’s staff, computing power and long-term R&D projects. Unlearn uses artificial intelligence to analyse patient health records and create a digital model for each participant in a clinical trial. Researchers can then use the digital twin to predict how each patient would fare if given a placebo treatment, enabling them to reduce the number of participants in the control group. Unlearn has received qualifications from the European Medicines Agency and the US Food and Drug Administration for its technology.
In a separate development, Twin Health, a digital twin company focused on digital therapeutics, has also raised $50m in a funding round. Twin Health’s technology uses AI to analyse user’s health records, wearable sensor data and questionnaire answers to provide recommendations for improving metabolic health. A study showed that after a year, participants who followed Twin Health’s AI-powered plan saw their average HbA1c levels drop from 9% to 6.1%.
